Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate

Paolo Perseghin, Carlo Gambacorti-Passerini, Lucia Tornaghi, Maria Dassi, Pietro Pioltelli, Matteo Parma, Federica Colnaghi, Giovanni Giudici, Elena Elli, Monica Fumagalli, Luisa Ponchio, Andrea Biondi, Enrico M. Pogliani

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Imatinib mesylate (IM) was introduced in chronic myeloid leukemia (CML) treatment in the late 1990s and substantially changed the therapeutic approach to the disease, by inducing complete cytogenetic response (CCR) in approximately 60 percent of cases. Nevertheless, some concerns exist about the duration of response to treatment and the onset of resistance to IM. STUDY DESIGN AND METHODS: Twenty-five chronic-phase CML patients in stable CCR (>6 months) treated for at least 1 year with IM at the standard dose (400 mg/ day) were mobilized with recombinant human granulocyte-colony-stimulating factor (Filgrastim) at 10 μg per kg for 4 to 6 days, with the aim of collecting at least 2 × 106 CD34+ cells per kg. Standard cytogenetic analysis and first-round and/or nested polymerase chain reaction were performed in basal and postmobilization samples to examine the presence of bcr-abl transcripts. RESULTS: CD34+ cells collection was successful in 16 patients, yielding a median of 3.01 × 106± 1.09 × 106 CD34+ cells per kg at the first attempt, and in 4 of the 9 remaining patients who were remobilized after a temporary withdrawal of IM, yielding a median of 2.65 × 106 ± 0.7 × 10 6 CD34+ cells per kg, with an overall 80 percent success rate. No correlation between mobilization and duration of the disease, length of IM treatment, or previous interferon-α and/or hydroxyurea treatment was found. CONCLUSIONS: Autologous CD34+ cells may be mobilized and collected in most CML patients who achieve CCR after IM treatment, with a view to possible use in the event that resistance to IM occurs in patients not eligible for allogeneic peripheral blood progenitor cell transplantation or those lacking an HLA-matched donor.

Original languageEnglish
Pages (from-to)1214-1220
Number of pages7
JournalTransfusion
Volume45
Issue number7
DOIs
Publication statusPublished - Jul 2005

ASJC Scopus subject areas

  • Hematology
  • Immunology

Fingerprint

Dive into the research topics of 'Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate'. Together they form a unique fingerprint.

Cite this